| RESEARCH ARTICLE |
|
| Year : 2014 | Volume
: 46
| Issue : 4 | Page : 413-415 |
Does tramadol affect coagulation status of patients with malignancy?
Ayten Bilir1, Meltem Olga Akay2, Dilek Ceyhan1, Neslihan Andıc1
1 Department of Anaesthesiology and Reanimation, Eskisehir Osmangazi University Medical School, Eskisehir, Turkey
2 Department of Hematology, Eskisehir Osmangazi University Medical School, Eskisehir, Turkey
Correspondence Address:
Dilek Ceyhan
Department of Anaesthesiology and Reanimation, Eskisehir Osmangazi University Medical School, Eskisehir
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.135954
Aim: The study investigated the direct effects of tramadol on the coagulation status of women with gynecologic malignancies in vitro.
Materials and Methods: Citrated whole-blood samples from 21 patients with gynecologic tumors were spiked ex vivo with 2 or 6 μl/ml tramadol. Thrombelastography (TEG) analysis was performed using ROTEM® to assess clotting time (CT), clot formation time (CFT) and maximum clot formation (MCF).
Results: In the INTEM assay, CT (P < 0.05) and CFT (P < 0.01) were significantly prolonged with tramadol at a 6 μl/ml concentration compared with baseline. There were no significant differences in MCF values between the baseline and the tramadol-treated samples (P > 0.05). Blood medicated with tramadol (6 μl/ml) clotted slowly (increased CT and CFT).
Conclusion: The changes observed by TEG demonstrated that tramadol impairs hemostasis in a concentration-dependent manner in the whole blood of women with gynecologic malignancies in vitro.
[FULL TEXT] [PDF]*
|
